Open Innovation Platform and Portfolio

We have developed a phase II clinical development campaign for two drug candidates for dengue: a platelet activating factor receptor antagonist (60P002) and an alpha glucosidase I inhibitor (60P001). We are exploring the utility of a third (60P004, a retinoid).

60P is also preparing for commercial launch of 60P003 for malaria prevention in 2018, following the completion of a cooperative research and development agreement with the U.S. Army.

Phases & Development Stages

About  |  Tropical Diseases  |  Products  |  Research  |  Responsibility  |  Investors  |  Media  |  Careers  |  Contact 

 1025 Connecticut Avenue NW, Suite 1000   Washington DC 20036 
Phone: 1-240-351-1167   Email: 

 Content © 2017. 60° Pharmaceuticals, LLC. All rights reserved.